Insulin Aspart
From PeptidePlaza, the free peptide reference · Entry #1088 · Metabolic · Sources fetched 2026-09-11 · Editorial standards
Insulin Aspart (also known as Aspart, Aspart insulin, Insulin B28asp, B28asp, Insulin) is a metabolic research peptide. Insulin Aspart is a rapid-acting human insulin analog that functions as an insulin receptor agonist, primarily used to improve glycemic control in patients with diabetes mellitus.
Insulin Aspart, also known as Aspart, is an FDA-approved rapid-acting human insulin analog. It acts as an agonist for the insulin receptor, facilitating glucose uptake and utilization. Approved in 1999, it is indicated for improving glycemic control in both adult and pediatric patients with diabetes mellitus. The compound is administered intravenously or subcutaneously and is marketed under the brand name NOVOLOG. Research has explored its use in various conditions including diabetes mellitus, leukemia, lymphoma, and gestational diabetes. Literature also focuses on its role as an insulin aspart biosimilar.
1 Mechanism of action
Insulin receptor agonist (agonist)
Primary targets: Insulin receptor
2 Reported effects
Effects below are those reported in the published literature cited on this page. They are not claims of clinical benefit and not medical advice.
2.1 Indicated / studied for
- Diabetes Mellitus
- Leukemia
- Lymphoma
- Diabetes, Gestational
- Hypertension
- Atherosclerosis
- Hypercholesterolemia
- Coronary Disease
2.2 Side effects
- Hypoglycemia
- Allergic reactions
- Local injection site reactions
- Lipodystrophy
- Rash
- Pruritus
3 Chemical and physical properties
| CAS number | 116094-23-6 |
|---|---|
| Molar mass | 5832 g/mol |
| Purity (typical) | Not independently verified |
| Half-life | ~81 minutes |
| Brand names | NOVOLOG |
| Route | INTRAVENOUS, SUBCUTANEOUS |
| Storage | −20 °C, lyophilised powder, desiccated |
| Solubility | Sterile water / bacteriostatic water |
| Receptors / targets | Insulin receptor |
4 Research dosages
Individualize and adjust the dosage of NOVOLOG based on route of administration, the individual's metabolic needs, blood glucose monitoring results and glycemic control goal.
5 Research studies (8)
- Aspart Insulin
(2026) - Insulin Aspart
(1994) · Review - Insulin aspart
Drugs (1999) · Review - Insulin Aspart-szjj: An Insulin Aspart Biosimilar
Clinical drug investigation (2026) · Review - [Insulin aspart(NN-X14)]
Nihon rinsho. Japanese journal of clinical medicine (2001) · Review - Pharmacokinetic and pharmacodynamic similarity between SAR341402 insulin aspart and Japan-approved NovoRapid in healthy Japanese subjects
Scientific reports (2021) · RCT - Pharmacological Properties of Faster-Acting Insulin Aspart
Current diabetes reports (2017) · Review - Meta-analysis of insulin aspart versus regular human insulin used in a basal-bolus regimen for the treatment of diabetes mellitus
Journal of diabetes (2013) · Meta-Analysis
6 Safety and risk profile
6.1 Regulatory status
Insulin Aspart is currently classified as FDA approved. Approval applies to specific clinical indications and dosing; research-grade material is not the approved product.
6.2 Contraindications
Conditions and populations in which use is contraindicated:
- During episodes of hypoglycemia
- Hypersensitivity to NOVOLOG or its excipients
6.3 Drug interactions
| Drug or class | Interaction | Risk |
|---|---|---|
| Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics | Increased risk of hypoglycemia | High |
| Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones | Decreased blood glucose lowering effect of NOVOLOG | High |
| Alcohol, beta-blockers, clonidine, and lithium salts | May increase or decrease the blood glucose lowering effect of NOVOLOG | Moderate |
| Pentamidine | May cause hypoglycemia, sometimes followed by hyperglycemia | Moderate |
| Beta-blockers, clonidine, guanethidine and reserpine | May blunt signs and symptoms of hypoglycemia | Moderate |
6.4 Long-term risks
- transmission of blood-borne pathogens from sharing pens or syringes
- hyperglycemia or hypoglycemia with changes in insulin regimen
- life-threatening hypoglycemia
- medication errors due to accidental mix-ups between insulin products
- severe, life-threatening, generalized allergy, including anaphylaxis
- life-threatening hypokalemia
- fluid retention and heart failure with concomitant use of thiazolidinediones (TZDs)
- hyperglycemia and ketoacidosis due to insulin pump device malfunction
7 Frequently asked questions
- What is Insulin Aspart used for?
- Insulin Aspart is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. It is a rapid-acting human insulin analog that helps manage blood sugar levels.
- How does Insulin Aspart work?
- Insulin Aspart works as an insulin receptor agonist. It binds to insulin receptors on cells, which promotes the uptake of glucose from the blood into cells, thereby lowering blood glucose levels.
- Is Insulin Aspart FDA approved?
- Yes, Insulin Aspart is FDA approved. It received its first approval in 1999 and is marketed under the brand name NOVOLOG for the treatment of diabetes mellitus.
- What are the side effects of Insulin Aspart?
- Common side effects of Insulin Aspart include hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus. Patients should be aware of these potential adverse reactions.
- What are the contraindications for Insulin Aspart?
- Insulin Aspart is contraindicated during episodes of hypoglycemia and in patients who have a hypersensitivity to NOVOLOG or any of its excipients. It should not be used in these situations.
8 References
- Insulin Aspart — compound summary PubChem. View source
- Insulin Aspart — molecule record ChEMBL. View source
- Insulin Aspart — FDA approved prescribing information U.S. Food and Drug Administration. View source
- Insulin Aspart — published literature (1,258 records) PubMed. View source
Related compounds
Entries that share a target, a mechanism, or a research area with Insulin Aspart.
Also targets Insulin receptor
Insulin Glargine is a long-acting human insulin analog and an insulin receptor agonist, FDA-approved to improve glycemic control in patients with type 1 and type 2 diabetes mellitus.
Also targets Insulin receptor
Insulin Lispro, also known as Lyumjev, is a rapid-acting human insulin analog that acts as an insulin receptor agonist.
Also targets Insulin receptor
Insulin Degludec is a long-acting human insulin analog and an insulin receptor agonist, FDA-approved for improving glycemic control in adults with type 2 diabetes mellitus.
Also targets Insulin receptor
Insulin Detemir, also known as Levemir, is a long-acting human insulin analog and an insulin receptor agonist used to improve glycemic control in patients with diabetes mellitus.
Also targets Insulin receptor
Insulin Zinc is an insulin receptor agonist that is FDA-approved for medical use.
Also targets Insulin receptor
Insulin Zinc, Extended is an insulin receptor agonist currently in Phase 2 clinical trials.